Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of
patients and can lead to a multitude of toxicities, suggesting the need for more targeted …

Lung cancer is the number one cause of cancer-related deaths. The malignancy is
characterized by dismal prognosis and poor clinical outcome mostly due to advanced-stage …

The development of monoclonal antibody treatments for successful tumor-targeted therapies
took several decades. However, the efficacy of antibody-based therapy is still confined and …

G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are
rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive …

In recent years the global market for monoclonal antibodies (mAbs) became a multi-billion-
dollar business. This success is mainly driven by treatments in the oncology and …

For centuries, plants have been exploited by mankind as sources of numerous cancer
chemotherapeutic agents. Good examples of anticancer compounds of clinical significance …

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a
promising anticancer strategy. The design of clinically effective antibody–drug conjugates …

Gastrointestinal cancers (GI) account for 26% of cancer incidences globally and 35% of all
cancer-related deaths. The main challenge is to target cancer specific antigens. Mucins are …